Sökning: onr:"swepub:oai:lup.lub.lu.se:2ec94e81-39de-4e14-864c-0d9db1212a17" >
One-year endometria...
One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
-
- Samsioe, Göran (författare)
- Lund University,Lunds universitet,Obstetrik och gynekologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Obstetrics and Gynaecology (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Dvorak, Vladimir (författare)
-
Genazzani, Andrea R (författare)
-
visa fler...
-
Hamann, Bernd (författare)
-
Heikkinen, Jorma (författare)
-
Mueck, Alfred O (författare)
-
Suzin, Jacek (författare)
-
Kawakami, Fernando T (författare)
-
Ferreira, Alberto (författare)
-
Sun, Dongming (författare)
-
Arguinzoniz, Miguel (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2007
- 2007
- Engelska.
-
Ingår i: Maturitas. - : Elsevier BV. - 1873-4111 .- 0378-5122. ; 57, s. 171-181
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
http://dx.doi.org/10...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To evaluate the safety and endometrial protection of low-dose transdermal estradiol (E2)/norethisterone acetate (NETA) patches (Estalis 25/125) in terms of post-treatment incidence of endornetrial hyperplasia/cancer after 1 year of treatment in postmenopausal women with intact uteri. Methods: Patients were randomized to receive either transdermal E2/NETA (delivering daily doses of E2 25 mu g and NETA 125 mu g; applied every 3-4 days) or oral E2/NETA (E2 1 mg and NETA 0.5 mg; given daily) in this open-label study. The primary variable was the incidence of endometrial hyperplasia/cancer based on endometrial biopsies; secondary variables included vaginal bleeding/spotting patterns, patch adhesion, safety and tolerability. Results: Six hundred and seventy-seven patients were randomized (507 in the transdermal group and 169 in the oral group; one did not receive study drug) and >80% completed the study. There were no cases of endometrial hyperplasia or cancer in either group and the upper limit of the one-sided 95% confidence interval in the transdermal group was 0.85%. Over time, both treatments were associated with a decreasing frequency of spotting/bleeding days. The overall incidence of adverse events (AEs) was comparable in both groups, and the majority was mild-to-moderate in intensity. Breast tenderness was the most frequently reported AE (transdermal 19.9% versus oral 28.4%). AEs related to the gastrointestinal system were more frequent with oral E2/NETA, and episodes of spotting and bleeding were more frequent with transdermal E2/NETA. Local skin tolerability of the transdermal matrix system was good. Conclusions: Transdermal E2/NETA (25 and 125 1 mu g) provided adequate endometrial protection in postmenopausal women when evaluated according to CPMP/CHMP criteria, achieved a high rate of amenorrhea, and was well tolerated.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Samsioe, Göran
-
Dvorak, Vladimir
-
Genazzani, Andre ...
-
Hamann, Bernd
-
Heikkinen, Jorma
-
Mueck, Alfred O
-
visa fler...
-
Suzin, Jacek
-
Kawakami, Fernan ...
-
Ferreira, Albert ...
-
Sun, Dongming
-
Arguinzoniz, Mig ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Reproduktionsmed ...
- Artiklar i publikationen
-
Maturitas
- Av lärosätet
-
Lunds universitet